Stock listing
NASDAQ:NCNA NuCana plc Stock
Follow NuCana plc into a list and get an email when it puts out news.
Share price · NASDAQ:NCNA
$0.75 USD -0.08 (-10.0%)
Close on Nov 20, 2026
- Day range
- $0.703 – $0.79 USDNov 20, 2026
- Volume
- 25,518 sharesNov 20, 2026
- Market cap
- $3.12M USDAt the close on Nov 20, 2026 · price × 4.16M shares outstanding
- 52-week range
- $0.703 – $4.55 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $153,164 USDMedian day 27,524 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NCNA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.75 | -0.083 | -10.0% | $0.79 | $0.79 | $0.703 | 25,518 | |
| $0.833 | -0.057 | -6.4% | $0.841 | $0.86 | $0.821 | 9,161 | |
| $0.89 | +0.027 | +3.1% | $0.89 | $0.94 | $0.774 | 43,311 | |
| $0.863 | -0.07 | -7.5% | $0.938 | $0.94 | $0.863 | 28,528 | |
| $0.933 | +0.003 | +0.3% | $0.94 | $0.94 | $0.93 | 12,764 | |
| $0.93 | -0.01 | -1.0% | $0.912 | $0.93 | $0.875 | 25,789 | |
| $0.94 | +0.005 | +0.5% | $0.946 | $0.96 | $0.90 | 41,526 | |
| $0.935 | -0.026 | -2.7% | $0.972 | $0.972 | $0.935 | 13,047 | |
| $0.961 | +0.023 | +2.4% | $0.95 | $0.998 | $0.95 | 13,831 | |
| $0.938 | +0.004 | +0.4% | $0.948 | $0.95 | $0.902 | 19,966 | |
| $0.934 | -0.086 | -8.4% | $0.99 | $0.99 | $0.90 | 27,524 | |
| $1.02 | +0.02 | +2.0% | $1.03 | $1.087 | $0.981 | 10,827 | |
| $1.00 | +0.02 | +2.0% | $1.07 | $1.07 | $0.985 | 13,906 | |
| $0.98 | -0.03 | -3.0% | $1.02 | $1.039 | $0.98 | 38,864 | |
| $1.01 | -0.03 | -2.9% | $1.04 | $1.06 | $1.00 | 19,200 | |
| $1.04 | -0.035 | -3.3% | $1.07 | $1.085 | $1.04 | 11,700 | |
| $1.075 | -0.025 | -2.3% | $1.10 | $1.12 | $1.06 | 31,100 | |
| $1.10 | +0.06 | +5.8% | $1.05 | $1.17 | $1.03 | 38,600 | |
| $1.04 | +0.055 | +5.6% | $1.02 | $1.04 | $1.00 | 27,100 | |
| $0.985 | +0.025 | +2.6% | $0.98 | $1.02 | $0.96 | 27,100 | |
| $0.96 | -0.002 | -0.2% | $0.973 | $0.988 | $0.95 | 31,800 | |
| $0.962 | -0.044 | -4.4% | $1.00 | $1.01 | $0.962 | 30,100 | |
| $1.006 | +0.029 | +3.0% | $0.985 | $1.035 | $0.983 | 29,300 | |
| $0.977 | -0.013 | -1.3% | $0.998 | $1.015 | $0.977 | 22,300 | |
| $0.99 | -0.03 | -2.9% | $1.02 | $1.03 | $0.97 | 46,700 | |
| $1.02 | -0.03 | -2.9% | $1.02 | $1.038 | $0.97 | 55,100 | |
| $1.05 | 0.00 | 0.0% | $1.05 | $1.065 | $1.03 | 38,000 | |
| $1.05 | -0.03 | -2.8% | $1.10 | $1.10 | $1.05 | 52,000 | |
| $1.08 | -0.02 | -1.8% | $1.10 | $1.14 | $1.08 | 28,600 | |
| $1.10 | -0.03 | -2.7% | $1.13 | $1.18 | $1.07 | 67,400 | |
| $1.13 | -0.01 | -0.9% | $1.14 | $1.14 | $1.10 | 34,600 | |
| $1.14 | +0.05 | +4.6% | $1.11 | $1.18 | $1.06 | 51,000 | |
| $1.09 | +0.03 | +2.8% | $1.08 | $1.14 | $1.05 | 50,900 | |
| $1.06 | -0.03 | -2.8% | $1.12 | $1.12 | $1.03 | 70,300 | |
| $1.09 | -0.08 | -6.8% | $1.18 | $1.22 | $0.948 | 320,900 | |
| $1.17 | -0.18 | -13.3% | $1.29 | $1.313 | $1.01 | 799,100 | |
| $1.35 | +0.14 | +11.6% | $1.29 | $1.44 | $1.26 | 3,304,300 | |
| $1.21 | -0.08 | -6.2% | $1.29 | $1.29 | $1.21 | 24,700 | |
| $1.29 | +0.01 | +0.8% | $1.32 | $1.37 | $1.26 | 23,600 | |
| $1.28 | -0.04 | -3.0% | $1.30 | $1.35 | $1.21 | 38,200 | |
| $1.32 | +0.01 | +0.8% | $1.31 | $1.34 | $1.272 | 9,200 | |
| $1.31 | -0.02 | -1.5% | $1.33 | $1.35 | $1.30 | 27,800 | |
| $1.33 | +0.01 | +0.8% | $1.348 | $1.38 | $1.30 | 20,400 | |
| $1.32 | -0.02 | -1.5% | $1.35 | $1.39 | $1.32 | 25,300 | |
| $1.34 | +0.01 | +0.8% | $1.33 | $1.385 | $1.32 | 11,000 | |
| $1.33 | +0.03 | +2.3% | $1.33 | $1.37 | $1.30 | 47,200 | |
| $1.30 | 0.00 | 0.0% | $1.31 | $1.332 | $1.30 | 19,200 | |
| $1.30 | -0.02 | -1.5% | $1.32 | $1.35 | $1.30 | 65,600 | |
| $1.32 | 0.00 | 0.0% | $1.34 | $1.37 | $1.311 | 13,600 | |
| $1.32 | -0.02 | -1.5% | $1.34 | $1.362 | $1.32 | 25,100 | |
| $1.34 | -0.03 | -2.2% | $1.36 | $1.375 | $1.34 | 26,200 | |
| $1.37 | -0.03 | -2.1% | $1.40 | $1.44 | $1.37 | 17,100 | |
| $1.40 | 0.00 | 0.0% | $1.42 | $1.43 | $1.40 | 21,600 | |
| $1.40 | -0.03 | -2.1% | $1.41 | $1.42 | $1.383 | 32,200 | |
| $1.43 | +0.04 | +2.9% | $1.38 | $1.44 | $1.362 | 49,100 | |
| $1.39 | +0.01 | +0.7% | $1.38 | $1.425 | $1.331 | 50,700 | |
| $1.38 | -0.09 | -6.1% | $1.44 | $1.45 | $1.355 | 103,700 | |
| $1.47 | -0.29 | -16.5% | $1.55 | $1.55 | $1.44 | 192,900 | |
| $1.76 | +0.29 | +19.7% | $1.45 | $1.90 | $1.41 | 1,018,300 | |
| $1.47 | -0.06 | -3.9% | $1.50 | $1.51 | $1.44 | 17,400 | |
| $1.53 | +0.06 | +4.1% | $1.48 | $1.53 | $1.465 | 12,800 | |
| $1.47 | 0.00 | 0.0% | $1.47 | $1.55 | $1.47 | 26,300 | |
| $1.47 | -0.05 | -3.3% | $1.52 | $1.52 | $1.47 | 13,400 | |
| $1.52 | -0.01 | -0.7% | $1.50 | $1.55 | $1.50 | 18,300 | |
| $1.53 | -0.02 | -1.3% | $1.53 | $1.55 | $1.50 | 18,400 |
Splits
2 splits since 2024 · NASDAQ:NCNA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-200 | Consolidation | |
| 1-for-25 | Consolidation |
- Ticker
- NASDAQ:NCNA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 20, 2026
NuCana Presents Preclinical Data Showing NUC-7738 Enhances Carfilzomib Activity in Multiple Myeloma Cell Lines at the 38th EORTC-NCI-AACR Symposium
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 41 slides
Latest news
NuCana Presents Preclinical Data Showing NUC-7738 Enhances Carfilzomib Activity in Multiple Myeloma Cell Lines at the 38th EORTC-NCI-AACR Symposium
Nov 20, 2026
Closed $0.75 (-10.0%) on Nov 20, 2026
NuCana Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 12, 2026
Closed $0.933 (+0.3%) on Nov 13, 2026
NuCana plc on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 2 in the last 12 months · 2 in all · newest Nov 20, 2026 · oldest 2026
- Decks
- 1 deck · latest October 2026
Valuation
Price/book 0.1× against a median of 0.7×: 2nd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$21.37M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.1×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.58
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| NuCana plc · NASDAQ:NCNA | US$3.12M | −US$21.37M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.58 |
| Xenetic Biosciences, Inc. · NASDAQ:XBIO | US$3.28M | −US$2.53M | n/a | −0.8× | n/a | 0.7× | −123.7% | 0.0× | 1.46 |
| Aprea Therapeutics, Inc. · NASDAQ:APRE | US$3.25M | −US$34.60M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 0.73 |
| Spago Nanomedical AB · OMXSTO:SPAGO | US$3.20M | US$22,063 | n/a | 5.6× | n/a | 1.0× | n/a | 0.0× | n/a |
| Kiora Pharmaceuticals, Inc. · NASDAQ:KPRX | US$3.19M | −US$12.81M | n/a | −12.8× | n/a | 0.2× | n/a | 0.0× | 1.54 |
| Azitra Inc · AMEX:AZTR | US$3.13M | −US$618,677 | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.60 |
| Revive Therapeutics Ltd. · CSE:RVV | US$3.10M | US$3.14M | n/a | n/a | n/a | n/a | n/a | n/a | 0.56 |
| Skye Bioscience, Inc. · NASDAQ:SKYE | US$3.10M | −US$1.71M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | 0.85 |
| Creative Medical Technology Holdings, Inc. · NASDAQ:CELZ | US$3.06M | −US$3.79M | n/a | −1,263× | n/a | 0.4× | n/a | 0.0× | 1.53 |
| Oncology Pharma Inc. · OTC:ONPH | US$3.04M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.62 |
| Imunon, Inc. · NASDAQ:IMNN | US$3.00M | US$5.90M | n/a | n/a | n/a | 1.1× | n/a | 2.6× | 0.57 |
| Median of the others | US$3.12M | −US$1.71M | −6.8× | 0.7× | −123.7% | 0.0× | 0.85 |
Forecasts
Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 104.00 USD · Analysts' mean
- EPS, year to Dec 2024
- -12.55 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Hugh Griffith | Founder, CEO & Board Member |
| Ian Webster | Chief Financial Officer |
| Theresa Bruce | Chief Operating Officer |
| Jeffrey Bloss | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Andrew Kay | Chairman |
| Cyrille Leperlier | Non Executive Director |
| Elliott Levy | Non Executive Director |
| Hugh Griffith | Founder, CEO & Board Member |
| Martin Mellish | Non Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 12, 2026 | −0.8% |
| Q2 2026 | Aug 13, 2026 | +11.2% |
| Q3 2025 | Nov 13, 2025 | −10.0% |
| Q2 2025 | Aug 20, 2025 | −7.0% |
| Q1 2025 | May 14, 2025 · Before open | +5.2% |
| Q4 2024 | Mar 20, 2025 · After close | −2.2% |
| Q3 2024 | Nov 25, 2024 · Before open | +2.4% |
| Q2 2024 | Aug 15, 2024 · After close | +6.4% |
| Q1 2024 | May 16, 2024 · After close | −2.7% |
| Q4 2023 | Mar 20, 2024 · After close | −12.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2023 | Nov 16, 2023 · After close | +1.7% |
| Q2 2023 | Aug 16, 2023 · After close | +9.9% |
| Q1 2023 | May 17, 2023 · After close | −2.6% |
| Q4 2022 | Mar 22, 2023 | −14.4% |
| Q3 2022 | Nov 16, 2022 · After close | −6.6% |
| Q2 2022 | Aug 17, 2022 · After close | −4.3% |
| Q1 2022 | Jun 2, 2022 · After close | +0.7% |
| Q3 2021 | Nov 18, 2021 · After close | +3.5% |
| Q2 2021 | Aug 19, 2021 · After close | 0.0% |
| Q1 2021 | May 19, 2021 · After close | +1.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 41 slides | October 2026 |
IPO
Priced at US$15.00 an ADS on Sep 27, 2017.
- Price
- US$15.00 an ADS
- ADSs offered
- 6,667,000 American depositary shares
- Offering size
- US$100 million
- Underwriters' option
- Up to 1,000,050 more ADSs
- Underwriters
- Citigroup, Jefferies, Cowen, William Blair · In the order on the cover
- ADSs delivered
- On or about Oct 2, 2017
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jun 26, 2017 |
| Filed publicly | Sep 1, 2017 |
| Amended twice | Newest Sep 21, 2017 |
| Shares registered with an exchange | Sep 22, 2017 |
| Declared effective by the SEC | Sep 27, 2017 |
| Final prospectus, with the price | Sep 29, 2017 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 29, 2017 |
| EFFECT · Notice that a registration is effective | Sep 27, 2017 |
| CERTNAS · Nasdaq's certificate of listing | Sep 25, 2017 |
| CORRESP · Letter to the SEC | Sep 25, 2017 |
| CORRESP · Letter to the SEC | Sep 25, 2017 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 22, 2017 |
| F-1/A · Registration statement, amended | Sep 21, 2017 |
| UPLOAD · Letter from the SEC | Sep 19, 2017 |
| F-1/A · Registration statement, amended | Sep 18, 2017 |
| CORRESP · Letter to the SEC | Sep 12, 2017 |
All 18 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Sep 12, 2017 |
| CORRESP · Letter to the SEC | Sep 6, 2017 |
| F-1 · Registration statement | Sep 1, 2017 |
| UPLOAD · Letter from the SEC | Aug 17, 2017 |
| DRSLTR · Letter to the SEC with a draft | Aug 4, 2017 |
| DRS/A · Draft registration statement, amended | Aug 4, 2017 |
| UPLOAD · Letter from the SEC | Jul 25, 2017 |
| DRS · Draft registration statement | Jun 26, 2017 |
Open IPO · From the cover of the final prospectus (424B4) filed Sep 29, 2017
Financials
Annual, in GBP
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 283.0K | 0 |
| Cost of revenue | 268.0K | 0 | 0 | 0 | 0 | |||||
| Gross profit | -268.0K | 0 | 0 | 283.0K | 0 | |||||
| Research and development | 12.7M | 18.0M | 25.1M | 36.4M | 36.8M | 25.9M | 19.7M | 16.8M | 17.7M | 7.90M |
| Selling, general and administrative | 8.10M | 4.99M | 6.06M | 7.29M | 8.53M | 7.05M | 5.95M | 5.18M | 4.57M | 1.14M |
| Operating income | -20.1M | -22.8M | -32.8M | -39.1M | -47.9M | -36.4M | -26.7M | -19.1M | -25.7M | -8.45M |
| Depreciation and amortization | 274.0K | 522.0K | 575.0K | 732.0K | 942.0K | 890.0K | 718.0K | 371.0K | 194.0K | 101.0K |
| EBITDA | -19.8M | -22.3M | -32.2M | -38.4M | -47.0M | -35.5M | -26.0M | -18.8M | -25.5M | -8.35M |
| Interest expense | 12.6M | 0 | 0 | 9.86M | 4.98M | 6.70M | 989.0K | 0 | 1.79M | 0 |
| Income before tax | -30.5M | -22.5M | -32.0M | -38.5M | -47.8M | -36.2M | -25.7M | -18.1M | -25.5M | -8.16M |
| Income tax | -1.17M | -3.45M | -4.40M | -6.43M | -7.27M | -5.49M | -4.24M | -4.22M | -2.40M | -2.12M |
| Net income | -29.4M | -19.0M | -27.6M | -32.0M | -40.5M | -30.7M | -21.4M | -13.8M | -23.1M | -6.05M |
| Earnings per share, basic | 0.00 | -0.26 | -0.53 | -0.61 | -0.78 | -4,049.89 | -3,311.99 | -2,164.53 | -3,686.52 | -950.80 |
| Earnings per share, diluted | 0.00 | -0.26 | -0.53 | -0.61 | -0.78 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 24.3M | 6.75M | 17.2M | 41.9M | 60.3M | 87.4M | 52.0M | 77.0M | 86.7M | 20.0M |
| Short-term investments | 0 | 0 | 0 | 0 | ||||||
| Receivables | 849.0K | 922.0K | 2.67M | 3.96M | 4.16M | 4.63M | 4.71M | 2.35M | 3.05M | 2.61M |
| Inventory | -11.3K | -14.4K | -13.2K | -1.80M | -3.05M | 3.20M | ||||
| Current assets | 26.9M | 12.3M | 25.0M | 54.9M | 71.6M | 101.8M | 65.2M | 83.6M | 94.0M | 25.8M |
| Property, plant and equipment | 658.0K | 197.0K | 521.0K | 866.0K | 851.0K | 1.19M | 1.11M | 427.0K | 358.0K | 18.0K |
| Goodwill | 0 | 0 | 0 | 0 | ||||||
| Total assets | 29.8M | 14.8M | 27.8M | 58.3M | 77.5M | 107.8M | 70.3M | 87.2M | 96.4M | 27.2M |
| Accounts payable | 522.0K | 2.71M | 3.38M | 4.80M | 1.83M | 2.26M | 2.41M | 2.46M | 1.12M | 728.0K |
| Current liabilities | 4.79M | 8.67M | 12.7M | 19.3M | 11.7M | 8.15M | 6.18M | 5.57M | 2.92M | 1.97M |
| Long-term debt | 0 | 0 | 0 | 0 | ||||||
| Total debt | 676.0K | 190.0K | 396.0K | 639.0K | 371.0K | 645.0K | 806.0K | 0 | 0 | 0 |
| Total liabilities | 5.51M | 8.82M | 12.9M | 19.8M | 11.9M | 8.56M | 6.75M | 5.59M | 2.94M | 1.97M |
| Shareholders' equity | 24.3M | 5.95M | 14.9M | 38.5M | 65.5M | 99.2M | 63.5M | 81.6M | 93.4M | 25.2M |
| Shares outstanding | 2.25M | 14.8K | 10.5K | 10.4K | 10.4K | 7.58K | 6.46K | 6.39K | 6.26K | 6.36K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -7.47M | -19.1M | -26.4M | -23.2M | -23.8M | -21.6M | -23.8M | -12.2M | -8.71M | -9.26M |
| Capital spending | 0 | -4.00K | -4.00K | -12.0K | -64.0K | -361.0K | -46.0K | -210.0K | -370.0K | -15.0K |
| Free cash flow | -7.47M | -19.1M | -26.4M | -23.2M | -23.9M | -22.0M | -23.9M | -12.4M | -9.08M | -9.28M |
| Cash from investing | 159.0K | 79.0K | 2.89M | 120.0K | -3.56M | -1.31M | -145.0K | -651.0K | -933.0K | 14.9M |
| Cash from financing | 25.0M | 8.18M | -53.0K | -161.0K | -98.0K | 61.8M | -47.0K | 207.0K | 77.7M | 200.0K |
| Dividends paid | 0 | 0 | 0 | 0 | ||||||
| Share buybacks | 125.0K | 207.0K | 80.0M | 200.0K | ||||||
| Change in cash | 17.7M | -10.9M | -23.6M | -23.2M | -27.5M | 38.9M | -24.0M | -12.7M | 68.1M | 5.87M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 20, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 12, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 30, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 13, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | Jun 8, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 1, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 14, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 6, 2026 | Current report | SEC |
Show 200 filings
This page holds 200 of 284 filings. Open Filings
Cap table
Built by 6ix from NuCana plc’s releases
- Common shares
- 4,161,971
- Fully diluted
- 4,161,971
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 4,161,971 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 4,161,971 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Elliott Levy Other companies: Editas Medicine, Inc. (Director · Since at least Apr 11, 2023); Omega Therapeutics Inc (Director · Jul 29, 2021 – Jun 20, 2024 · Past) | Non Executive Director · Since at least Mar 18, 2026 |
| Andrew Kay | Chairman · Since at least Nov 5, 2026 |
| Cyrille Leperlier | Director · Since at least Mar 18, 2026 |
| David James Harrison | Head of Translational Medicine · Since at least Mar 18, 2026 |
| Hugh Griffith | Chief Executive Officer, Director · Since at least Mar 18, 2026 |
| Ian Webster | Chief Financial Officer · Since at least Nov 5, 2026 |
| Jeffrey Bloss | Chief Medical Officer · Since at least Mar 18, 2026 |
| Martin Mellish | Non Executive Director · Since at least Nov 5, 2026 |
| Theresa Bruce | Chief Operating Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about NuCana plc.